Why Spyre Therapeutics (SYRE) Stock Is Up Today

Spyre Therapeutics (SYRE) is up 7.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued investor enthusiasm around Spyre’s positive mid-stage ulcerative colitis data, combined with a fresh analyst price-target increase that appears to have reinforced bullish sentiment. The move also fits a broader pattern of traders positioning for additional clinical readouts expected later in 2026.

Details:

Spyre recently reported positive Phase 2 Part A induction results for SPY002 in moderate-to-severe ulcerative colitis, with the candidate meeting its primary endpoint and posting clinical remission and endoscopic improvement figures that support a strong competitive profile.

An analyst raised its price target on the stock to $120 from $84 while keeping a positive rating, citing the inflammatory bowel disease data and the possibility of further upside if upcoming studies also deliver.

The company has highlighted a busy catalyst calendar, including additional proof-of-concept readouts across its SKYLINE and SKYWAY programs this year, which can increase speculative demand in biotech names.

Spyre also entered the year with a large cash position and said its funding runway extends into the second half of 2029, which may help investors look past near-term losses and focus on pipeline execution.

Sources:

Spyre Therapeutics, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$SYRE Insider Trading Activity

$SYRE insiders have traded $SYRE stock on the open market 43 times in the past 6 months. Of those trades, 0 have been purchases and 43 have been sales.

Here’s a breakdown of recent trading of $SYRE stock by insiders over the last 6 months:

FUNDS MANAGEMENT LLC FAIRMOUNT sold 4,684,781 shares for an estimated $399,658,667
SHELDON SLOAN (Chief Medical Officer) has made 0 purchases and 11 sales selling 102,958 shares for an estimated $7,354,471.
CAMERON TURTLE (Chief Executive Officer) has made 0 purchases and 18 sales selling 90,000 shares for an estimated $5,307,162.
SCOTT L BURROWS (Chief Financial Officer) has made 0 purchases and 12 sales selling 52,500 shares for an estimated $3,861,797.
MICHAEL THOMAS HENDERSON sold 20,000 shares for an estimated $2,000,000

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$SYRE Hedge Fund Activity

We have seen 106 institutional investors add shares of $SYRE stock to their portfolio, and 49 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL INTERNATIONAL INVESTORS removed 1,746,412 shares (-50.0%) from their portfolio in Q1 2026, for an estimated $88,089,021
CALIGAN PARTNERS LP added 878,127 shares (+inf%) to their portfolio in Q1 2026, for an estimated $44,292,725
BANK OF AMERICA CORP /DE/ added 808,366 shares (+192.6%) to their portfolio in Q1 2026, for an estimated $40,773,981
POINT72 ASSET MANAGEMENT, L.P. removed 662,351 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $33,408,984
PARADIGM BIOCAPITAL ADVISORS LP added 490,000 shares (+33.4%) to their portfolio in Q1 2026, for an estimated $24,715,600
COMMODORE CAPITAL LP removed 475,865 shares (-19.9%) from their portfolio in Q1 2026, for an estimated $24,002,630
CAPITAL WORLD INVESTORS added 466,392 shares (+233.0%) to their portfolio in Q1 2026, for an estimated $23,524,812

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$SYRE Analyst Ratings

Wall Street analysts have issued reports on $SYRE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Deutsche Bank issued a "Buy" rating on 06/04/2026

To track analyst ratings and price targets for $SYRE, check out Quiver Quantitative's $SYRE forecast page.

$SYRE Price Targets

Multiple analysts have issued price targets for $SYRE recently. We have seen 11 analysts offer price targets for $SYRE in the last 6 months, with a median target of $95.0.

Here are some recent targets:

David Hoang from Deutsche Bank set a target price of $135.0 on 06/23/2026
Julian Harrison from BTIG set a target price of $112.0 on 06/15/2026
Alex Thompson from Stifel set a target price of $107.0 on 05/06/2026
Samantha Semenkow from Citigroup set a target price of $97.0 on 05/06/2026
Debanjana Chatterjee from Jones Trading set a target price of $95.0 on 04/17/2026
David Nierengarten from Wedbush set a target price of $80.0 on 04/14/2026
Yanan Zhu from Wells Fargo set a target price of $90.0 on 04/14/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.